Phuturdex › Diseases › Coronavirus disease
Drugs in development · updated 30 October 2026
Coronavirus disease: drugs in development
As of 30 October 2026 there are 15 active clinical trials (recruiting or ongoing, phases I–III) on 18 drugs for coronavirus disease. 11 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Ibuzatrelvir | III | 2 | NCT06679140 |
| DAS181 | III | 1 | NCT03808922 |
| Tozorakimab | III | 1 | NCT05624450 |
| Clazakizumab | II | 1 | NCT04494724 |
| Ebselen | II | 1 | NCT04484025 |
| MRNA-1273 | II | 1 | NCT07808697 |
| MRNA-1283 | II | 1 | NCT07808697 |
| ACU-026-001-1 | I | 1 | NCT07902583 |
| Boost-2867 | I | 1 | NCT07221162 |
| CpG 7909 | I | 1 | NCT07221162 |
| OCU500 | I | 1 | NCT07536308 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BaricitinibOlumiant® | III | 1 | NCT06631287 |
| NitazoxanideAlinia® | III | 1 | NCT04382846 |
| RemdesivirVeklury | III | 1 | NCT07013474 |
| TozinameranBNT162b2 | III | 1 | NCT07798648 |
| TradipitantNereus® | III | 1 | NCT04326426 |
| Dornase alfaPulmozyme | II | 1 | NCT04445285 |
| Aluminum Hydroxide Suspension | I | 1 | NCT07221162 |
Sorted by most advanced phase and number of active trials.
All 18 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- COVID-19 104 drugs
- Post-Acute COVID-19 Syndrome 44 drugs
- Influenza 68 drugs
- Fatigue 24 drugs
- Myalgic encephalomyelitis/chronic fatigue syndrome 7 drugs
- Community-acquired pneumonia 45 drugs
- Pneumonia 63 drugs
- Respiratory tract infection 46 drugs
- Cognitive dysfunction 94 drugs
- Immunologic Deficiency Syndromes 17 drugs
- Non-small-cell lung carcinoma 726 drugs
- Tinnitus 12 drugs
Broader categories
- RNA virus infectious disease 8 drugs
- Infection 71 drugs
- Respiratory disease 57 drugs
- Virus Diseases 26 drugs
- Viral pneumonia 6 drugs
- Pneumonia 63 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D018352 “Coronavirus Infections”.